Health Technology Peptidream Inc. Business Summary
PeptiDream Inc. engages in the biopharmaceutical business that includes research and development of non standard peptide therapeutics. It produces stable, and potent non-standard macrocyclic peptides based on its proprietary Peptide Discovery Platform System (PDPS). The company was founded by Kiichi Kubota and Hiroaki Suga on July 3, 2006 and is headquartered in Kawasaki, Japan.
Financial Highlights
Dec 2019
JPY USD Revenue 2,074.67M 19.03M Gross Profit 661.06M 6.06M Operating income -1,774.33M -16.27M Income before tax -1,413.07M -12.96M Net income -976.92M -8.96M EBITDA -1,261.79M -11.57M Diluted EPS -7.80 -0.07 Dividends Per Share 0 0 Total Assets 17,817.34M 163.95M Total liabilities 839.05M 7.72M Total equity 16,978.28M 156.22M Operating cash flow 241.98M 2.21M Currency in JPY Currency in USD
Historical Data Jun 2015 Jun 2016 Jun 2017 Jun 2018 Dec 2019 Revenue
2,474.49M
4,327.87M
4,895.74M
6,426.89M
2,074.67M
Gross Profit
1,752.47M
3,241.08M
3,530.02M
4,648.26M
661.06M
Operating income
1,391.12M
2,548.08M
2,490.41M
2,978.48M
-1,774.33M
Income before tax
1,493.37M
2,365.81M
2,624.15M
3,151.73M
-1,413.07M
Net income
1,004.16M
1,581.28M
1,890.75M
2,335.21M
-976.92M
EBITDA
1,494.19M
2,691.08M
2,685.28M
3,491.82M
-1,261.79M
Diluted EPS
7.83
12.26
14.56
17.79
-7.80
Dividends Per Share
0
0
0
0
0
Total Assets
7,738.44M
11,956.40M
13,628.45M
16,512.83M
17,817.34M
Total liabilities
826.01M
1,713.64M
1,447.65M
1,804.11M
839.05M
Total equity
6,912.43M
10,242.75M
12,180.80M
14,708.71M
16,978.28M
Operating cash flow
1,386.14M
1,533.05M
1,530.77M
1,022.71M
241.98M
Jun 2015 Jun 2016 Jun 2017 Jun 2018 Dec 2019 Revenue
21.58M
37.08M
44.87M
58.24M
19.03M
Gross Profit
15.28M
27.77M
32.35M
42.12M
6.06M
Operating income
12.13M
21.83M
22.82M
26.99M
-16.27M
Income before tax
13.02M
20.27M
24.05M
28.56M
-12.96M
Net income
8.76M
13.54M
17.33M
21.16M
-8.96M
EBITDA
13.03M
23.05M
24.61M
31.64M
-11.57M
Diluted EPS
0.06
0.10
0.13
0.16
-0.07
Dividends Per Share
0
0
0
0
0
Total Assets
63.24M
116.54M
121.29M
149.07M
163.95M
Total liabilities
6.75M
16.70M
12.88M
16.28M
7.72M
Total equity
56.49M
99.84M
108.40M
132.79M
156.22M
Operating cash flow
12.09M
13.13M
14.03M
9.26M
2.21M
Valuation Measures
Dec 2019
PER -- ROA -5.69% ROE -6.16% Operating margin -85.52% Profit margin -47.08%
Key executives
President & Representative Director:
Patrick Crawford Reid
Director, Manager-Research & Development:
Keiichi Masuya
Manager-Public & Investor Relations:
Toshiyuki Iwata Shareholders
KUBOTA KIICHI (11.2%)
SUGA HIROAKI (8.7%)
J.O. Hambro Capital Management Ltd. (7.8%)
JPMorgan Asset Management (Japan) Ltd. (4.1%)
Asset Management One Co., Ltd. (4.1%)
REID PATRICK C (3.6%)
BlackRock Fund Advisors (3.0%)
Nomura Asset Management Co., Ltd. (2.7%)
Invesco Advisers, Inc. (2.3%)
The Vanguard Group, Inc. (1.9%)
Related Companies
Peptidream Board Incentive Plan
Peptidream Employee Incentive Plan
PharmaDesign, Inc. (Japan) /Pharma Research Bus/
PharmaDesign, Inc. (Japan)
Competitors
Aileron Therapeutics, Inc.
Apellis Pharmaceuticals, Inc.
Bicycle Therapeutics Plc Sponsored ADR
MorphoSys AG
Protagonist Therapeutics, Inc.
UCB S.A.
Copyright © 2021 FactSet Research Systems Inc. All rights reserved.
Last Updated on 15 Jan, 2021
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter Find out more
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
Cookie Policy
to learn how you can update your cookie settings.
Accept & Continue
Close
